// App-Quantinova.ai

: USE OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: THE RELATIONSHIP OF IMMUNOGENICITY WITH THERAPY

Researchers

Presenter

  • Galina Tarasova

Principal Investigators

  • Boris Belov

  • Daria Bukhanova

  • Maria Cherkasova

  • Sergey Solovyev

  • Elena Aseeva

  • Tatiana Reshetnyak

  • Tatiana Popkova

Medical Centers

  • VA Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia

Locations

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • BLM helicase

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Pneumococcal polysaccharide vaccine

  • Hydroxychloroquine

  • Mycophenolic acid

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Glucocorticoid

  • Oraprine

  • Methotrexate

  • Prednisolone

  • Belimumab

  • Rituximab

  • PPV-23

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved